Photo taken from C. Ola Landgren/X
Apr 14, 2024, 12:56
Carl Ola Landgren: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs
Carl Ola Landgren, Professor of Medicine, Chief of Myeloma Division at University of Miami, shared a post on X:
“I started the EVIDENCE meta-analysis in 2009. After 15 years of work, I will present 4/12 at ODAC: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs?”
Procced to the video.
Source: Carl Ola Landgren/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 18, 2025, 15:20
Jan 18, 2025, 14:58
Jan 18, 2025, 14:50
Jan 18, 2025, 14:43
Jan 18, 2025, 14:40
Jan 18, 2025, 14:33